[1] |
Tsuchiya N, Sawada Y, Endo I, et al. Biomarkers for early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(37): 10573-10583.
|
[2] |
Wallace MC, Preen D, Jeffrey GP, et al. The evolving epidemiology of hepatocellular carcinoma: a global perspective[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(6):765-779.
|
[3] |
Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma[J]. Semin Diagn Pathol, 2017, 34(2):153-159.
|
[4] |
Mao YP, Xie FY, Liu LZ, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging[J]. Int J Radiat Oncol Biol Phys, 2009, 73(5):1326-1334.
|
[5] |
Zhang J, Cui Z, Feng G, et al. RBM5 and p53 expression after rat spinal cord injury: implications for neuronal apoptosis[J]. Int J Biochem Cell Biol, 2015, 60:43-52.
|
[6] |
Zhang YP, Liu KL, Wang YX, et al. Down-regulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR-432-5p/beta-catenin feedback loop[J]. FASEB J, 2019, 33(10):10973-10985.
|
[7] |
Qian T, Shi S, Xie L, et al. miR-938 promotes cell proliferation by regulating RBM5 in lung adenocarcinoma cells[J]. Cell Biol Int, 2019, DOI: 10.1002/cbin.11233[Epub ahead of print].
|
[8] |
Wang Y, Jiang XM, Feng ZX, et al. Long noncoding RNA PCAT-1accelerates the metastasis of pancreatic cancer by repressing RBM5[J]. Eur Rev Med Pharmacol Sci, 2019, 23(17):7350-7355.
|
[9] |
Yang ZT, An F, Hu JD, et al. Long noncoding RNA AFAP1-AS1 accelerates the proliferation and metastasis of prostate cancer via inhibiting RBM5 expression[J]. Eur Rev Med Pharmacol Sci, 2019, 23(8):3284-3290.
|
[10] |
Yang ZG, Ma XD, He ZH, et al. miR-483-5p promotes prostate cancer cell proliferation and invasion by targeting RBM5[J]. Int Braz J Urol, 2017, 43(6):1060-1067.
|
[11] |
Guo LY, Qin CF, Zou HX, et al. LncRNA AB073614 promotes the proliferation and inhibits apoptosis of cervical cancer cells by repressing RBM5[J]. Eur Rev Med Pharmacol Sci, 2019, 23(6): 2374-2379.
|
[12] |
Kobayashi T, Ishida J, Shimizu Y, et al. Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer[J]. Tumour Biol, 2017, 39(3):1010428317694547.
|
[13] |
Jiang Y, Sheng H, Meng L, et al. RBM5 inhibits tumorigenesis of gliomas through inhibition of Wnt/beta-catenin signaling and induction of apoptosis[J]. World J Surg Oncol, 2017, 15(1):9.
|
[14] |
Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97(3): 230-238.
|
[15] |
Cui F, Shen L, Li L, et al. Prevention of chronic hepatitis B after3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23(5):765-772.
|
[16] |
Fitzmorris P, Shoreibah M, Anand BS, et al. Management of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2015, 141(5): 861-876.
|
[17] |
Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region[J]. J Gastroenterol, 2013, 48(6):681-688.
|
[18] |
Kythreotou A, Siddique A, Mauri FA, et al. PD-L1[J]. J Clin Pathol, 2018, 71(3):189-194.
|
[19] |
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
|
[20] |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173.
|
[21] |
Serrano P, Hammond JA, Geralt M, et al. splicing site recognition by synergy of three domains in splicing factor RBM10[J]. Biochemistry, 2018, 57(10):1563-1567.
|
[22] |
Sun Y, Bao Y, Han W, et al. Autoregulation of RBM10 and cross-regulation of RBM10/RBM5 via alternative splicing-coupled nonsense-mediated decay[J]. Nucleic Acids Res, 2017, 45(14):8524-8540.
|
[23] |
Loiselle JJ, Roy JG, Sutherland LC. RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5[J]. PLoS One, 2017, 12(6):e0180258.
|
[24] |
Jamsai D, Watkins DN, O'connor AE, et al. In vivo evidence that RBM5 is a tumour suppressor in the lung[J]. Sci Rep, 2017, 7(1): 16323.
|
[25] |
Prabhu VV, Devaraj N. Regulating RNA binding motif 5 gene expression-a novel therapeutic target for lung cancer[J]. J Environ Pathol Toxicol Oncol, 2017, 36(2):99-105.
|
[26] |
Jackson TC, Kotermanski SE, Kochanek PM. Whole-transcriptome microarray analysis reveals regulation of Rab4 by RBM5 in neurons[J]. Neuroscience, 2017(361):93-107.
|
[27] |
Payancé A, Dioguardi Burgio M, Peoc'h K, et al. Biological response under treatment and prognostic value of protein induced by vitamin K absence or antagonist-Ⅱ in a French cohort of patients with hepatocellular carcinoma[J]. Eur J Gastroenterol Hepatol, 2020, 32(10):1364-1372.
|